The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparative safety profiles of lutetium-177 and enzalutamide: A pharmacovigilance study and disproportionality analysis using real world data.
 
Manas Pustake
No Relationships to Disclose
 
Mohammad Arfat Ganiyani
No Relationships to Disclose
 
Atulya Khosla
No Relationships to Disclose
 
Avi Harisingani
No Relationships to Disclose
 
Nouman Aziz
No Relationships to Disclose
 
Saif Syed
No Relationships to Disclose
 
Mostafa Eysha
No Relationships to Disclose
 
Mohanad Elchouemi
No Relationships to Disclose
 
Fatma Nihan Akkoc Mustafayev
No Relationships to Disclose
 
Khalis Mustafayev
No Relationships to Disclose
 
Manmeet Ahluwalia
Stock and Other Ownership Interests - doctible; MedInnovate Advisors LLC; MimiVax; TriSalus Life Sciences
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - AlloVir; Anheart Therapeutics; Apollomics; Autem Therapeutics; Bayer; Bugworks; Cairn Therapeutics; Caris Life Sciences; Equillium; GlaxoSmithKline; InSightec; Janssen; Menarini Group; Modifi Bio; NH TherAguix; Nuvation Bio; Prelude Therapeutics; Pyramid Biosciences; SDP Oncology; Siemens Healhineers/Varian Medical Systems; Sumitomo Dainippon Pharma Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst); Seagen (Inst)
Other Relationship - Idorsia (I); ResMed (I)
 
Rohan Garje
Research Funding - Exelixis (Inst); Janssen Oncology (Inst)